April 29, 2025 02:08 AM EDTUpdated 06:07 AM
People
Startups

Oc­ta­gon Ther­a­peu­tics shuts down af­ter 'un­re­solved bi­ol­o­gy ques­tion­s'

Kyle LaHucik

Senior Reporter

Oc­ta­gon Ther­a­peu­tics is wind­ing down op­er­a­tions, its CEO post­ed on LinkedIn on Mon­day.

The biotech, with op­er­a­tions in Cam­bridge, MA, and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA de­lays PDU­FA date for small biotech, rais­ing ques­tions about im­pact of agency cuts

Pfiz­er launch­es a new wave of cost cuts, ex­pects $7.7B in to­tal sav­ings through 2027

As­traZeneca, No­var­tis ex­e­cute ‘US for US’ strat­e­gy as phar­ma tar­iffs near

As­traZeneca posts an­oth­er Truqap study fail, says Chi­na im­port tax could triple

Boehringer’s up­dat­ed re­sults in HER2-mu­tat­ed lung can­cer im­press

sponsored

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

A service from the Financial Times